skip to Main Content

Encycle Therapeutics raises $2.85 million to advance macrocycle platform and pipeline

Encycle TherapeuticsTORONTO, ON (September 30, 2015) — Encycle Therapeutics, Inc., a University of Toronto spin-off company created in partnership with MaRS Innovation, announced today that it has completed a $2.85 million (CAD) financing led by Takeda Pharmaceutical Company Ltd. through its venture capital arm, Takeda Ventures, Inc., with Accel-Rx Health Sciences Accelerator, BDC Capital and MaRS Investment Accelerator Fund.

This news was covered in PEHub, BetaKit and TechVibes.

The funding will support ongoing development of Encycle’s unique nacellin platform chemistry and advance the company’s pipeline of novel therapeutics. It will also allow the company to build on research collaborations with several pharmaceutical companies and ultimately position it for a series A transaction and/or additional strategic partnerships.

“Our proprietary chemistry has the potential to unlock myriad therapeutic avenues, including via intracellular protein-protein interactions that cannot be targeted with conventional therapeutics,” said Dr. Jeffrey Coull, president and CEO of Encycle Therapeutics; upon the closing, Coull joined Encycle’s board of directions. “This funding is critical to enable the company to further explore the vast potential of our technology and to de-risk it to the extent that major transactions will be enabled.”

“Our goal is to make an impact on patients’ lives by turning science and technology into life-changing medicines. We are enthusiastic about Encycle’s technology and its potential in the context of ‘undruggable’ proteins,” said Dr. Ilan Zipkin, senior investment director at Takeda.

“Encycle’s growing momentum reflects MaRS Innovation’s efforts to shift the Canadian paradigm for technology transfer,” said Dr. Raphael Hofstein, chairman of the Encycle Therapeutics Board of Directors and president and CEO of MaRS Innovation. “This company began with promising research in Dr. Andrei Yudin’s laboratory at the University of Toronto. With crucial support from many players along the Ontario-Quebec life sciences corridor, MaRS Innovation collaborated with him to package and protect the technology, launch the company and hire experienced management. The success of this funding round bodes well for its future growth and success.”

Continue Reading

Ontario Government, University of Toronto, and MaRS secure Johnson & Johnson Innovation, JLABS for Toronto – first JLABS Incubator outside of United States

Partners for JLABS @ Toronto include Janssen Inc., MaRS Innovation and seven of MI’s 15 member institutions

 Minister of Economic Development, Employment and Infrastructure Brad Duguid announces the arrival of JLABS @ Toronto in the MaRS Discovery District. First row, left to right: Chris Halyk, president of Janssen Inc.; Melinda Richter, head of JLABS, Johnson & Johnson; Dr. Meric Gertler, president, University of Toronto; Minister Duguid; Dr. Ilse Treuricht, CEO MaRS Discovery District; Dr. Raphael (Rafi) Hofstein, president and CEO MaRS Innovation, and Robert Urban, head of Johnson & Johnson Innovation Boston. Second row: Dr. Robert Howard, president and CEO St. Michael's Hospital; Dr. Catherine Zahn, president and CEO CAMH; Dr. Barry McLellan, president and CEO Sunnybrook Health Sciences Centre; Dr. Peter Pisters, president & CEO University Health Network; Dr. Jim Woddgett, director of research, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital; and Dr. Michael Apkon, president and CEO, The Hospital for Sick Children.

Minister of Economic Development, Employment and Infrastructure Brad Duguid announces the arrival of JLABS @ Toronto in the MaRS Discovery District. First row, left to right: Chris Halyk, president of Janssen Inc.; Melinda Richter, head of JLABS, Johnson & Johnson; Dr. Meric Gertler, president, University of Toronto; Minister Duguid; Dr. Ilse Treuricht, CEO MaRS Discovery District; Dr. Raphael (Rafi) Hofstein, president and CEO MaRS Innovation, and Robert Urban, head of Johnson & Johnson Innovation Boston. Second row: Dr. Robert Howard, president and CEO St. Michael’s Hospital; Dr. Catherine Zahn, president and CEO CAMH; Dr. Barry McLellan, president and CEO Sunnybrook Health Sciences Centre; Dr. Peter Pisters, president & CEO University Health Network; Dr. Jim Woddgett, director of research, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital; and Dr. Michael Apkon, president and CEO, The Hospital for Sick Children.

 

TORONTO, Sept. 8, 2015 — The Ontario Government, University of Toronto, and MaRS Discovery District (MaRS) today announced a collaboration with Janssen Inc. to launch the successful Johnson & Johnson Innovation, JLABS incubator model in Toronto.

This announcement has been covered in the Toronto Star, Metro News Canada, Sing Tao Daily, OurWindsor.ca, FierceBiotech, BioCentury, MedCity News, BioSpace, Biotechnology Focus, Lab Product News, ChinaNews.com, Pan European Networks, Economic Development Blog, BetaKit, Torontoist, and TechVibes.

It was also featured news on Rx&D‘s and Life Sciences Ontario‘s websites.

The new facility, called JLABS @ Toronto, will open in spring of 2016 at MaRS Discovery District and will support start-ups with lab space, programs, and potential investment partners as they work to build important, successful early-stage companies.

“The arrival of the Johnson & Johnson Innovation, JLABS model to MaRS’ West Tower reinforces Ontario’s position as one of the world’s leading life sciences clusters,” said Brad Duguid, Minister of Economic Development, Employment and Infrastructure. “JLABS @ Toronto will support researchers and entrepreneurs across the province and accelerate the development of Ontario companies while connecting Toronto to potential Johnson & Johnson collaborators and investors.”

“Research and innovation are fundamental to the mission of the University of Toronto,” said Dr. Meric S. Gertler, President, University of Toronto. “We host a vibrant entrepreneurial ecosystem featuring nine campus-led accelerators under the umbrella of our Banting & Best Centre for Innovation and Entrepreneurship. The addition of JLABS to this ecosystem will further propel the creation of new companies and new jobs, and ultimately new healthcare solutions that will benefit individuals and our society for years to come.”

“Toronto is home to a vibrant and prolific healthcare and life sciences community led by academic hospitals, world-class research institutions, top scientists, and a strong start-up ecosystem. For these reasons, Toronto is a natural choice for our first international expansion of JLABS,” said Melinda Richter, Head of JLABS. “The Johnson & Johnson Family of Companies has long been active within the Toronto Ontario community, forming many important collaborations. Today we are pleased to begin an even deeper relationship with this important community. Our new location, within a University of Toronto site, close to our hospital collaborators, and neighbouring the financial centre of Canada, will deliver great opportunities and impact for emerging biomedical technology entrepreneurs.”

Continue Reading

UTEST company Nvest listed in Omers’ Canadian #FinTech Infographic

Nvest Logo“Over the past few weeks, a few members of our investment team took the seopportunity to map out FinTech companies from coast-to-coast, focusing on those that are developing next generation technologies or technology enabled services,” wrote the OMERS Venture team in a blog post accompanying a new #fintech infographic that lists 89 Canadian businesses operating in the financial start-up sector.

Nvest, part of the third UTEST cohort, in included in the graphic (see below). The infographic’s release was also covered in BetaKit in a story by Doug Soltys noting the sector’s growth in just six months:

What a difference six months makes. Today, Canadian VC giant OMERS Ventures released a similar infographic, tracking 89 different Canadian FinTech startups from Vancouver to St. John’s, essentially a 40 per cent increase. OMERS also noted that these 89 companies have attracted over $1 billion in capital since 2010.

Here’s where OMERS Ventures’ take on where the sector going:

Continue Reading

Law firm partners with UTEST program to offer legal advice to early-stage startups

TORONTO, ON (August 10, 2015) — Toronto-based law firm Aird & Berlis LLP (A&B) has become the sponsoring legal partner to the University of Toronto Early-Stage Technology Program (UTEST).

This partnership was covered in TechVibes, Law Times and the Financial Post‘s Legal Post blog.

Welcome to the table: Aird & Berlis are joining MaRS Innovation and the University of Toronto in supporting UTEST, an early-stage incubator for start-up companies that has graduated 17 companies and counting.
Welcome to the table: Aird & Berlis are joining MaRS Innovation and the University of Toronto in supporting UTEST, an early-stage incubator for start-up companies that has graduated 17 companies and counting.

UTEST is a 12-month incubation and acceleration program co-managed by the University of Toronto (U of T) and MaRS Innovation that allows selected U of T-affiliated early-stage startup companies to incorporate, use office space, receive mentorship and access $30,000 in funding, with opportunities for follow-on funding from MaRS Innovation.

In 2014, UTEST was named one of Canada’s most promising start-up accelerators in an online series by BetaKit, a digital publication that covers Canadian technology.

“We are thrilled to partner with A&B and leverage their legal expertise for our startups and emerging companies,” said Kurtis Scissions, who co-directs UTEST with MI’s Mike Betts. “To date, 17 companies, including Granata Decision Systems, Whirlscape, Crowdmark, eQOL and TrendMD, have successfully graduated from our program. We look forward to adding A&B’s Startups Team of lawyers to our mentorship group for the UTEST program, beginning in 2015.”

Continue Reading

ChipCare closes oversubscribed $5 million series A financing

With lead investment from Puffin Partners, the Ontario, Canada-based company is taking lifesaving blood-testing technology to low- and middle-income countries

ChipCare device
ChipCare’s technology will provide simple-to-use, mobile, lab-quality blood testing for remote health settings. The University of Toronto start-up company’s first HIV-related test, targeted at linking people with HIV to appropriate treatments, is scheduled to hit the market in late 2016.

TORONTO, March 3, 2015 — ChipCare Corporation, a University of Toronto start-up company commercializing a handheld, blood-testing platform for HIV and other infectious and non-communicable diseases has closed a $5.045 million Series A financing to bring its first-generation product to market while further developing the platform’s next generation products.

The Wall Street Journal‘s Venture Capital Dispatch blog, Yonge Street Media, BetaKit and PEHub covered this announcement, along with the University of Toronto’s news site and a follow-up BetaKit article on how smartphones and start-ups are increasing access to healthcare. Information about past ChipCare  investment rounds and other company information is available in our ChipCare news archive.

Insufficient access in remote health settings to simple, accurate and affordable diagnostic tests makes it difficult to provide timely, evidence-based clinical care. Current technology within central laboratories cannot fulfill the existing need in remote health settings, including community level health facilities, remote communities, emergency departments, ICUs and doctors’ offices. The result is millions of preventable deaths from infectious and non-communicable diseases globally, reduced economic growth, and limited human development.

Chipcare CorporationChipCare’s technology will provide simple-to-use, mobile, lab-quality blood testing in remote health settings. The company’s first HIV-related test, targeted at linking people with HIV to appropriate treatments, is scheduled to hit the market in late 2016. The company is developing other products that leverage unique attributes of ChipCare’s technology.

Puffin Partners, LP, of Dallas, Texas led the financing round, which includes existing investors MaRS Innovation and Maple Leaf Angels, and new investors, including the Winfield Venture Group, Epic Capital, and additional Canadian and U.S. Angel investors.

Continue Reading

Ontario government announces over $400,000 for eQOL’s home dialysis technology

EQOL logoSAULT STE. MARIE, February 13, 2015  — eQOL, a Sault Ste. Marie-based company working to enhance patient independence and a graduate of the second University of Toronto Early-Stage Technology (UTEST) incubator’s second cohort, has received $435,475 from the Ontario Government. David Orazietti, MPP for Sault Ste. Marie, made the announcement on February 13, 2015.

This announcement was covered by BetaKit, The Sault Star and SooToday.com.

The funding, which includes $415,000 through the Northern Ontario Heritage Fund Corporation (NOHFC) and $20,475 to hire an intern under the Northern Ontario Internship Program also through NOHFC, will allow eQOL to complete clinical studies using their Dialysis Platform for Communication, Assistance and Training (DiCAT) product.

David Orazetti and Binh Nguyan
MPP David Orazetti (left) and Binh Nguyan (centre), CEO of eQOL, at the Northern Ontario Internship Program announcement on February 13, 2014. Photo courtesy of SooToday.com.

“With this support from our government, eQOL is able to use their innovative new technology in clinical studies – the first step towards commercializing the technology,” said Orazietti. “This software will not only enhance the quality of life for dialysis patients, but will also benefit our health care system and community as it streamlines processes and alleviates strain on hospital resources.”

DiCAT, a mobile technology solution for independent/home dialysis, aims to simplify and reduce the intimidation that patients experience with this self-care process. Its iPad and web-based applications provide enhanced connectivity, access to resources, and process management, which will promote a shift from in-centre care to in-home care. Successfully completing the clinical study and implementing DiCAT will allow patients who live far away from healthcare centres to receive care at home without having to relocate, which will have a great impact in northern regions.

Continue Reading

UTEST announces third cohort of U of T software start-ups

Products range from wearable digital coaches to socially-drive financial investment tools

utestTORONTO (Dec. 2, 2014) — The University of Toronto Early-Stage Technology (UTEST) incubator, co-directed by U of T’s Innovations & Partnerships Office (IPO) and MaRS Innovation, has announced its third cohort of computer science start-up companies.

Betakit and Electronic Products &Technology covered this announcement; TechVibes featured Syncadian and Onyx Motion in recent features. The U of T magazine also featured Syncadian and CEO Hanna Janossy in this recent profile.

The five companies and the diverse sectors they target are (scroll for full company descriptions):

  • FlatFab Inc. — 3D printing (designing 3D objects that print in 2D)
  • ICE3 Power Technologies Inc. — hardware (universal charger for portable devices)
  • Onyx Motion Inc. — wearables (digital coaching)
  • Nvest Inc. — financial investing (socially-driven stock recommendations)
  • Syncadian Inc. — digital health (fatigue management for enterprise clients)

Past graduates include Whirlscape, TrendMD, Crowdmark, eQOL and Granata Decision Systems, among others.

Continue Reading

BlueDot, formerly BioDiaspora Inc., secures Series A with Horizons Ventures

Toronto-based commercial arm of BioDiaspora research program tracks global spread of infectious diseases in real-time; fourth MI company to reach Series A

BlueDot logoTORONTO (Dec. 2, 2014) — BlueDot, a Toronto-based social benefit corporation founded by Dr. Kamran Khan, an infectious disease physician and scientist, tracks and predicts the global spread of infectious diseases.

Spun off from St. Michael’s Hospital in partnership with MaRS Innovation (and formerly known as BioDiaspora Inc.), BlueDot, has secured a Series A venture capital funding from Horizons Ventures. Funded by Sir Li Ka-shing, Horizons invests in what they call “game-changing disruptive tech,” and has a proven track record in making early-stage investments (i.e., Facebook, Skype, Waze, Siri and Spotify).

TechVibes and MedCity News covered BlueDot’s Series A announcement, as did PE Hub and BetaKit. Read the BlueDot press release here.

The company is the fourth in MaRS Innovation’s portfolio to reach Series A. MaRS Innovation provided $400,000 in seed funding and worked with BlueDot and St. Michael’s to incorporate the company and develop its initial business strategy, intellectual property protection strategy and go-to-market plan. The Ontario Centres of Excellence also provided $140,000 in commercialization grants that helped BlueDot get off the ground.

BlueDot is the commercial arm of Dr. Khan’s academic research program called BioDiaspora, which was developed at the Li Ka Shing Knowledge Institute of St. Michael’s. BioDiaspora models how infectious diseases can spread and impact populations globally by analyzing big data such as the annual movements of more than 3 billion travelers on commercial flights; human, animal and insect population data; climate data from satellites; and news reports of disease outbreaks. The program was inspired by the Toronto’s SARS crisis in 2003 and its capabilities scientifically validated in prestigious academic journals such as the Lancet and the New England Journal of Medicine.

Visualization of the final destinations of travellers departing countries in West Africa with widespread and intense Ebola virus transmission
Visualization of the final destinations of travelers departing countries in West Africa with widespread and intense Ebola virus transmission. Source: http://bluedot.global/work

During its development, BlueDot’s platform technology was used by numerous international agencies, including the U.S. Centers for Disease Control, the World Health Organization, the European Centre for Disease Prevention and Control and the Public Health Agency of Canada to evaluate emerging infectious disease threats, including those during global mass gatherings such as the Olympics and the hajj.

Continue Reading
Back To Top